PIM1 Antikörper (AA 25-86)

Produktnummer ABIN7169141

Produktdetails anti-PIM1 Antikörper

Target: PIM1 (Pim-1 Oncogene (PIM1))

Bindungsspezifität: AA 25-86

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PIM1 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Serine/threonine-protein kinase pim-1 protein (25-86AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu PIM1

Target: PIM1 (Pim-1 Oncogene (PIM1))

Andere Bezeichnung: PIM1 (PIM1 Produkte)

Synonyme: PIM antikoerper, Pim-1 antikoerper, PIM1 antikoerper, pim antikoerper, pim-1 antikoerper, pim3 antikoerper, Pim-1 proto-oncogene, serine/threonine kinase antikoerper, proviral integration site 1 antikoerper, Pim-1 proto-oncogene, serine/threonine kinase L homeolog antikoerper, PIM1 antikoerper, Pim1 antikoerper, pim1 antikoerper, pim1.L antikoerper

Hintergrund:

Background: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Aliases: Oncogene PIM 1 antibody, Oncogene PIM1 antibody, PIM 1 antibody, pim 1 kinase 44 kDa isoform antibody, Pim 1 kinase antibody, pim 1 oncogene (proviral integration site 1) antibody, Pim 1 oncogene antibody, PIM antibody, PIM1 antibody, pim1 kinase 44 kDa isoform antibody, PIM1_HUMAN antibody, Pim2 antibody, PIM3 antibody, Proto oncogene serine/threonine protein kinase Pim 1 antibody, Proto-oncogene serine/threonine-protein kinase Pim-1 antibody, Proviral integration site 1 antibody, Proviral integration site 2 antibody

UniProt: P11309

Pathways: Glycosaminoglycan Metabolic Process